

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/020,368 12/11/2001 Alex Wah Hin Yeung 506822000100 7590 03/11/2004 EXAMINER ALEX WAH HIN YEUNG JONES, DAMERON LEVEST GARDEN TERRACE I, 8 OLD PEAK ROAD, APT. 1B, ART UNIT PAPER NUMBER MIDLEVELS, 1616 HONG KONG DATE MAILED: 03/11/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No.	Applicant(s)
	10/020,368	YEUNG, ALEX WAH HIN
	Examiner	Art Unit
	D. L. Jones	1616
The MAILING DATE of this communication appears on the cover sheet with the correspondence address		
THE REPLY FILED 07 January 2000 FAILS TO PLACE. Therefore, further action by the applicant is required to avifinal rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	ation. A proper reply to a
PERIOD FOR REPLY [check either a) or b)]		
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of ti (2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any earned patent term adjustment. See 37 Cl	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THe date on which the petition under 37 CFF f extension and the corresponding amount to the shortened statutory period for reply one later than three months after the mailing date.	g date of the final rejection. IE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension unt of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.		
2. The proposed amendment(s) will not be entered because:		
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);		
(b) they raise the issue of new matter (see Note below);		
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or		
(d) They present additional claims without canceling a corresponding number of finally rejected claims.		
NOTE: <u>See Continuation Sheet</u> .		
3. Applicant's reply has overcome the following rejection(s):		
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).		
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:		
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.		
7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>1-20</u> .		
Claim(s) withdrawn from consideration:		
B. ☐ The drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.		
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)		
0. Other:	(D. L. Jones Primary Examiner Art Unit: 1616

DAMERON L. JONES
PRIMARY EXAMINER
39/04

Continuation of 2. NOTE: Applicant's amendment is not persuasive and would require additional searching and consideration. First, Applicant needs to put all claims in ascending order with status identifiers. In other words, the after final amendment submitted on 1/7/04 does not comply with the revised format of amendments (please see the attached yellow sheet regarding how amendments should be submitted to the office). Secondly, Applicant's response is confusing because the Examiner has not withdrawn claims 1, 2, and 7-20. Did Applicant intend to cancel the claims? Thirdly, applicant's response to the 112 rejections is not persuasive. As set forth in the office action mailed 12/12/03, the specification is enabling for renal cell carcinoma, not all other diseases (i.e., all cancers). Hence, in order to overcome the rejections, it is suggested that (1) the claims be amended to encompassed the invention for which Applicant is enabled. The invention is not enabled for all types of cancer except renal cell carcinoma which is disclosed in the specification. OR (2) Applicant point to support in the specification (page and line number(s)) wherein other types are diseases (i.e., cancers) are disclosed.